The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies

Journal of Virology

Volumn 79, Issue 23, 2005, Pages 14632-14639

  Yim, Kevin C ^a   Carroll, Clifford J ^a   Tuyama, Ana ^b   Cheshenko, Natalia ^b   Carlucci, Maria Josefina ^b   Porter, David D ^a   Prince, Gregory A ^a   Herold, Betsy C ^b  

^a Virion Systems Inc   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DEXAMETHASONE; MEDROXYPROGESTERONE; NAPHTHALENESULFONIC ACID DERIVATIVE; PLACEBO; PRO 2000 GEL; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; COTTON RAT; DRUG EFFICACY; FEMALE; GEL; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; INBRED STRAIN; KIDNEY; LIVER; LUNG; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; RODENT; SEXUALLY TRANSMITTED DISEASE; SIGMODON HISPIDUS; VIRUS REACTIVATION;

ANIMALS; DISEASE MODELS, ANIMAL; HERPES GENITALIS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; PREVENTIVE MEDICINE; SIGMODONTINAE;

ANIMALIA; CAVIA PORCELLUS; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS; RODENTIA; SIGMODON; SIGMODON HISPIDUS;

EID: 27744537436     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.23.14632-14639.2005     Document Type: Article

References (39)

1. Blanco, J. C., L. Pletneva, M. Boukhvalova, J. Y. Richardson, K. A. Harris, and G. A. Prince. 2004. The cotton rat: an underutilized animal model for human infectious diseases can now be exploited using specific reagents to cytokines, chemokines, and interferons. J. Interferon Cytokine Res. 24:21-28.
2. Blanco, J. C., J. Y. Richardson, M. E. Darnell, A. Rowzee, L. Pletneva, D. D. Porter, and G. A. Prince. 2002. Cytokine and chemokine gene expression after primary and secondary respiratory syncytial virus infection in cotton rats. J. Infect. Dis. 185:1780-1785.
3. Bourne, N., D. I. Bernstein, J. Ireland, A. J. Sonderfan, A. T. Profy, and L. R. Stanberry. 1999. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J. Infect. Dis. 180:203-205.
4. Brock, B. V., S. Selke, J. Benedetti, J. M. Douglas, Jr., and L. Corey. 1990. Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes. JAMA 263:418-420.
5. Celum, C. L. 2004. The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 11(Suppl. 1):36A-45A.
6. Cheshenko, N., M. J. Keller, V. MasCasullo, G. A. Jarvis, H. Cheng, M. John, J. H. Li, K. Hogarty, R. A. Anderson, D. P. Waller, L. J. Zaneveld, A. T. Profy, M. E. Klotman, and B. C. Herold. 2004. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob. Agents Chemother. 48:2025-2036.
7. Cohen, M. S. 1998. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 351:5-7.
8. Corey, L., and R. Ashley. 2004. Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Herpes 11(Suppl. 3):170A-174A.
9. Corey, L., A. Wald, C. L. Celum, and T. C. Quinn. 2004. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35:435-445.
10. Gillgrass, A. E., A. A. Ashkar, K. L. Rosenthal, and C. Kaushic. 2003. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J. Virol. 77:9845-9851.
11. Gillgrass, A. E., S. A. Fernandez, K. L. Rosenthal, and C. Kaushic. 2005. Estradiol regulates susceptibility following primary exposure to genital herpes simplex virus type 2, while progesterone induces inflammation. J. Virol. 79:3107-3116.
12. Kaushic, C., A. A. Ashkar, L. A. Reid, and K. L. Rosenthal. 2003. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J. Virol. 77:4558-4565.
13. Keller, M. J., M. E. Klotman, and B. C. Herold. 2003. Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus. J. Antimicrob. Chemother. 51:1099-1102.
14. Keller, M. J., A. Tuyama, M. J. Carlucci, and B. C. Herold. 2005. Topical microbicides for the prevention of genital herpes infection. J. Antimicrob. Chemother. 55:420-423.
15. Koelle, D. M., and A. Wald. 2000. Herpes simplex virus: the importance of asymptomatic shedding. J. Antimicrob. Chemother. 45(Suppl. T3):1-8.
16. Lewandowski, G., M. N. Zimmerman, L. L. Denk, D. D. Porter, and G. A. Prince. 2002. Herpes simplex type 1 infects and establishes latency in the brain and trigeminal ganglia during primary infection of the lip in cotton rats and mice. Arch. Virol. 147:167-179.
17. Linehan, M. M., S. Richman, C. Krummenacher, R. J. Eisenberg, G. H. Cohen, and A. Iwasaki. 2004. In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa. J. Virol. 78:2530-2536.
18. Mayer, K. H., S. A. Karim, C. Kelly, L. Maslankowski, H. Rees, A. T. Profy, J. Day, J. Welch, and Z. Rosenberg. 2003. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women, AIDS 17:321-329.
19. Mbopi Keou, F. X., R. Mbu, P. Mauclere, A. Andela, E. Tetanye, R. Leke, G. Chaouat, F. Barre-Sinoussi, P. Martin, and L. Belec. 1998. Antenatal HIV prevalence in Yaounde, Cameroon. Int. J. STD AIDS 9:400-402.
20. McClelland, R. S., C. C. Wang, J. Overhaugh, B. A. Richardson, L. Corey, R. L. Ashley, K. Mandaliya, J. Ndinya-Achola, J. J. Bwayo, and J. K. Kreiss. 2002. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 16:2425-2430.
21. Ottolini, M. G., S. J. Curtis, D. D. Porter, A. Mathews, J. Y. Richardson, V. G. Hemming, and G. A. Prince. 2002. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob. Agents Chemother. 46:2299-2302.
22. Ottolini, M. G., S. R. Curtis, A. Mathews, S. R. Ottolini, and G. A. Prince. 2002. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant. 29:117-120.
23. Ottolini, M. G., D. D. Porter, J. C. Blanco, and G. A. Prince. 2002. A cotton rat model of human parainfluenza 3 laryngotracheitis: virus growth, pathology, and therapy. J. Infect. Dis. 186:1713-1717.
24. Parr, M. B., and E. L. Parr. 2003. Intravaginal administration of herpes simplex virus type 2 to mice leads to infection of several neural and extraneural sites. J. Neurovirol. 9:594-602.
25. Parr, M. B., and E. L. Parr. 2003. Vaginal immunity in the HSV-2 mouse model. Int. Rev. Immunol. 22:43-63.
26. Poli, G., and Fauci, A. S. 1995. A role of cytokine in the pathogenesis of human immunodeficiency virus infection, p. 421-449. In B. Aggarwahl and R. Puri (ed.), Human cytokines: their role in disease and therapy. Blackwell Science, Cambridge, MA.
27. Prince, G. A., S. J. Curtis, K. C. Yim, and D. D. Porter. 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82:2881-2888.
28. Prince, G. A., J. J. Mond, D. D. Porter, K. C. Yim, S. J. Lan, and D. M. Klinman. 2003. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J. Virol. 77:13156-13160.
29. Prince, G. A., and D. D. Porter. 1996. Treatment of parainfluenza viras type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. J. Infect. Dis. 173:598-608.
30. Spencer, S. E., I. E. Valentin-Bon, K. Whaley, and A. E. Jerse. 2004. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J. Infect. Dis. 189:410-419.
31. Stanberry, L. R., E. R. Kern, J. T. Richards, T. M. Abbott, and J. C. Overall, Jr. 1982. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J. Infect. Dis. 146:397-404.
32. Stanberry, L. R., E. R. Kern, J. T. Richards, and J. C. Overall, Jr. 1985. Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology 24:226-231.
33. Van Damme, L., G. Ramjee, M. Alary, B. Vuylsteke, V. Chandeying, H. Rees, P. Sirivongrangson, L. Mukenge-Tshibaka, V. Ettiegne-Traore, C. Uaheowitchai, S. S. Karim, B. Masse, J. Perriens, and M. Laga. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977.
34. Van Damme, L., A. Wright, K. Depraetere, I. Rosenstein, V. Vandersmissen, L. Poulter, M. McKinlay, E. Van Dyck, J. Weber, A. Profy, M. Laga, and V. Kitchen. 2000. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm. Infect. 76:126-130.
35. Wald, A., J. Zeh, S. Selke, T. Warren, A. J. Ryncarz, R. Ashley, J. N. Kreiger, and L. Corey. 2000. Reactivation of genital herpes simplex virus type 2 in asymptomatic seropositive persons. New Engl. J. Med. 342:844-850.
36. Weber, J., A. Nunn, T. O'Connor, D. Jeffries, V. Kitchen, S. McCormack, J. Stott, N. Almond, A. Stone, and J. Darbyshire. 2001. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS 15:1563-1568.
37. Wyde, P. R., D. K. Moore-Poveda, N. J. Daley, and H. Oshitani. 1999. Replication of clinical measles virus strains in hispid cotton rats. Proc. Soc. Exp. Biol. Med. 221:53-62.
38. Wyde, P. R., D. K. Moore-Poveda, E. De Clercq, J. Neyts, A. Matsuda, N. Minakawa, E. Guzman, and B. E. Gilbert. 2000. Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections. Antimicrob. Agents Chemother. 44:1146-1152.
39. Wyde, P. R., K. J. Stittelaar, A. D. Osterhaus, E. Guzman, and B. E. Gilbert. 2000. Use of cotton rats for preclinical evaluation of measles vaccines. Vaccine 19:42-53.